Google DeepMind Spinoff Plans AI-Designed Drug Trials by Year-End

Isomorphic Labs, a subsidiary of Alphabet, aims to accelerate drug development with artificial intelligence and has partnered with major pharmaceutical companies.

• Isomorphic Labs, a Google DeepMind spinoff, is aiming to begin clinical trials for its first AI-designed drugs by the end of 2025, according to CEO Demis Hassabis.
• The company has partnered with pharmaceutical giants Eli Lilly and Novartis on six drug development programs targeting diseases such as cancer, cardiovascular conditions, and neurodegeneration.
• AI is expected to significantly reduce the time and cost of drug discovery, which traditionally takes 12-15 years and costs approximately $2.6 billion per drug.
• Challenges remain, including the need for high-quality training data and the limitations of AI in generating entirely new scientific hypotheses.
• The broader AI-driven drug discovery market is growing rapidly, with over $60 billion invested globally and more than 460 startups working in the space.

0 Articles